First Fast PCR Saliva COVID-19 Tests for Point of Care Conducted in Canada - Read Press Release

Sal6830 Corporate Landing Page

Make your workplace a safe space

Songbird was the first company in Canada to offer point of care rapid testing during the height of the pandemic. Now, Songbird is introducing Sal6830, the world’s first saliva-based PCR test, to its range of authorized DNA/RNA-identification technologies.

Authorized by Health Canada and the FDA for emergency use, Sal6830 combines the speed and convenience of an antigen test with the accuracy of a PCR test.

Find out if Sal6830 is right for your workplace.


Easy-to-collect saliva
sample makes testing comfortable
for team members.

Results in under 30 minutes

Results in 27 minutes
means less employee downtime.

Anytime, anywhere

PCR testing can be conducted anywhere, including wellness rooms and nurses offices.

Minimizes false positives

Health Canada authorized* point-of-care technology captures intact virus, an important indicator of a current COVID-19 infection.

When you need to be sure

As case counts climb, the risk for COVID-19 exposure in the office increases. By adding Health Canada authorized* PCR testing to the other preventative measures such as distancing, masking, and santizing, companies benefit in many ways:

  • Minimize the chance of office transmission. Sal6830 provides provides accurate results in less than half an hour.
  • Provide employees with peace of mind. Returning to the office can be less stressful, if testing programs are in place.
  • Partner with established testing experts. Having already deployed successful testing programs for businesses over the course of the pandemic, Songbird programs are customized to the needs of each business.


A Breakthrough in COVID-19 Testing

  • Painless sampling: Eliminates the need for uncomfortable swab testing.
  • Detects a current COVID-19 infection:  Traditional PCR tests may detect fragments of the virus from a previous COVID-19 infection. Sal6830 was designed to capture the intact virus, a key indicator of a current and transmissible infection. 
  • Robust with existing variants: Clinically evaluated during both the Delta and Omicron waves, the multiple SARS-CoV-2 gene targets allow for robust detection of current variants and protect against obsolescence from future variants.

Authorized for emergency use by Health Canada

Authorized for emergency use by the FDA under an EUA for use by authorized laboratories or under a CIA waiver.

Developed with the support from the National Institutes of Health (NIH), Rapid Acceleration of Diagnostics (RADx) initiative.